Why Psyence Biomedical Ltd.’s (PBM) Stock Is Up 9.01%
As of Friday, July 25, Psyence Biomedical Ltd.’s PBM share price has surged by 9.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Commentary & Analysis
Why Psyence Biomedical Ltd.’s (PBM) Stock Is Up 14.21%
As of Friday, July 25, Psyence Biomedical Ltd.’s PBM share price has surged by 14.21%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | PBM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.8 | $217.7 | 9% |
|
| Shares Out (Mil) | 0.9 | 53.7 | 4% |
|
| Institutional Ownership | 89.8% | 92.9% | 57% |
|
| Float (Mil) | 1.1 | 41.4 | 3% |
|
| Beta | 1.73 | 0.95 | 87% |
|
| Avg Daily Volume (000s) | 37 | 583 | 26% |
|
| Price Change (52-week) |
(81.2%) | 45.5% | 9% |
|
| Growth | PBM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PBM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($44) | 32% |
|
| EPS (TTM) | ($12.560) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($33) | 22% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $9 | $175 | 7% |
|
| Valuation | PBM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.56 | 2.11 | 12% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PBM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (55.8%) | (47.1%) | 10% |
|
| ROE | (58.6%) | (54.1%) | 14% |
|
| Liabilities to Assets | 3.5% | 29.0% | 1% |
|
| F-Score | 1 | 2 | na |
|
Psyence Biomedical Ltd. did not pass any screens on 10/19/2026.
